In late February, the Food amd Drug Administration approved its fifth novel prescription drug or biologic for 2014: AstraZeneca PLC’s Myalept (metreleptin for injection) for the treatment of a very rare fat disorder called generalized lipodystrophy.
Patients with congenital or acquired general lipodystrophy (also known as Lawrence-Seip syndrome) have a near-absence of body fat in the...